NCT02062827View on ClinicalTrials.gov

Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 25, 2013

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2027

Conditions
Recurrent Glioblastoma MultiformeProgressive Glioblastoma MultiformeAnaplastic Astrocytoma or Gliosarcoma
Interventions
BIOLOGICAL

M032 (NSC 733972)

A single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Alabama at Birmingham

OTHER